obeticholic acid Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
5155 459789-99-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • obeticholic acid
  • ocaliva
  • 6-ECDCA
  • 6ECDCA
  • INT-747
obeticholic acid is an agonist for FXR, a nuclear receptor expressed in the liver and intestine
  • Molecular weight: 420.63
  • Formula: C26H44O4
  • CLOGP: 5.36
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 3
  • TPSA: 77.76
  • ALOGS: -4.58
  • ROTB: 5

Drug dosage:

DoseUnitRoute
10 mg O

Approvals:

DateAgencyCompanyOrphan
Dec. 12, 2016 EMA Intercept Pharma Ltd
May 27, 2016 FDA INTERCEPT PHARMACEUTICALS INC

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 1371.62 52.22 292 338 46541 3338688
Pruritus generalised 111.76 52.22 27 603 5842 3379387
Drug dose omission 89.22 52.22 35 595 38397 3346832
Fatigue 87.30 52.22 47 583 107193 3278036
Blood alkaline phosphatase increased 82.52 52.22 24 606 10529 3374700
Constipation 78.30 52.22 30 600 30782 3354447
Abdominal distension 60.14 52.22 20 610 13556 3371673
Rash 57.19 52.22 31 599 70790 3314439
Jaundice 53.30 52.22 17 613 10090 3375139
Blood bilirubin increased 52.65 52.22 17 613 10492 3374737

Pharmacologic Action:

SourceCodeDescription
ATC A05AA04 ALIMENTARY TRACT AND METABOLISM
BILE AND LIVER THERAPY
BILE THERAPY
Bile acids and derivatives
CHEBI has role CHEBI:62868 hepatoprotective agent
FDA EPC N0000192561 Farnesoid X Receptor Agonist
FDA MoA N0000192560 Farnesoid X Receptor Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Primary cholangitis indication 17266006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.92 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 8058267 Feb. 21, 2022 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 8377916 Feb. 21, 2022 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 8058267 Feb. 21, 2022 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 8377916 Feb. 21, 2022 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2021 NEW CHEMICAL ENTITY
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2021 NEW CHEMICAL ENTITY
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2023 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2023 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bile acid receptor Nuclear hormone receptor AGONIST EC50 7.00 SCIENTIFIC LITERATURE DRUG LABEL
G-protein coupled bile acid receptor 1 GPCR EC50 7 CHEMBL

External reference:

IDSource
CHEBI:43602 CHEBI
0462Z4S4OZ UNII
9084 INN_ID
016875 NDDF
1798288 RXNORM
31698 MMSL
d08442 MMSL
4035786 VANDF
N0000192568 NDFRT
720257002 SNOMEDCT_US
3435 IUPHAR_LIGAND_ID
D09360 KEGG_DRUG
CHEMBL566315 ChEMBL_ID
DB05990 DRUGBANK_ID
C464660 MESH_SUPPLEMENTAL_RECORD_UI
447715 PUBCHEM_CID
CHC PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-005 TABLET, FILM COATED 5 mg ORAL NDA 20 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-010 TABLET, FILM COATED 10 mg ORAL NDA 20 sections